The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).
Lecia V. Sequist
Consultant or Advisory Role - Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)
Research Funding - Clovis
Jean-Charles Soria
No relevant relationships to disclose
Shirish M. Gadgeel
Research Funding - Clovis
Heather A. Wakelee
Research Funding - Clovis
D. Ross Camidge
Consultant or Advisory Role - Clovis (U)
Andrea Varga
No relevant relationships to disclose
Benjamin J. Solomon
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Novartis; Pfizer; Roche
Vassiliki Papadimitrakopoulou
Consultant or Advisory Role - Clovis (U)
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis; Merck; Novartis
Sarah S. Jaw-Tsai
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Lisa Caunt
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Paramjit Kaur
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Lindsey Rolfe
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jonathan Wade Goldman
Honoraria - Clovis
Research Funding - Clovis